'Stunning' 4% yearly rise in R&D share has emerging biopharma dominating pipeline
30 Mar 2023
Preview
Source: FierceBiotech
Big Pharmas represented just 23% of pipeline activity in 2022.
Emerging biopharmas have gradually taken over the R&D pipeline, producing two-thirds of all new drugs in 2022, a finding one financial biotech player called "stunning."
"Emerging biopharma has been rising at roughly 4% a year for each of the last five years," Tim Opler, Ph.D., managing director for life sciences investment bank Torreya, said during a March 29 presentation of IQVIA’s report on global R&D trends. Opler, citing the IQVIA data, dubbed the stat an "absolutely stunning finding."
"Go back to, say, the year 2005," Opler said. "If someone told you that two-thirds of our industry would be driven on the R&D side by emerging biopharma—it would be unthinkable. If one were to project that trend forward, what it would suggest is that we could have a day when we do this talk, say in 2027 or 2028, where 80% of the industry's pipeline is coming from emerging companies."
So-called emerging biopharmas (EBPs)—a term for companies with less than $200 million in R&D spending and annual sales lower than $500 million—were responsible for 67% of 2022’s R&D pipeline, according to IQVIA's report. This is a jump from about 63% pipeline ownership the year prior, 51% five years ago and 33% back in 2002 ago, according to the report.
However, the rise of EBPs underscores the slowly receding presence of Big Pharma in R&D.
“If two-thirds of the pipeline is from emerging biopharma, what's going on with Big Pharma?” Opler asked during the presentation. “I do worry a bit about Big Pharma R&D productivity and I think that's a topic to be addressed in the five years ahead.”
Big Pharmas represented just 23% of pipeline activity in 2022, a steep drop from 48% back in 2002. The decline has somewhat softened in the last five years, according to IQVIA's chart, though the number of EBPs has shot up 26% in the same period.
The number of R&D deals between pharmas also dipped 25% from 2021, while an increasing share of deals involved EBPs with larger companies.
This isn’t to say Big Pharma isn’t still greatly involved in biotech. In 2022, the 15 largest pharmas put down a record-setting $138 billion for R&D, a 43% jump from five years prior and a number that represents 18.8% of their recorded sales.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.